PDCD1 and neoplasm: These include the upregulation of non-classical HLA-E molecules, both on tumor cells and antigen-presenting cells (dendritic cells and macrophages) the impairment of activating receptors such as NKG2D, and the induction of inhibitory immune checkpoints such as PD-1 [11].